Bausch + Lomb (BLCO) Revenue & Revenue Breakdown
Bausch + Lomb Revenue Highlights
Latest Revenue (Y)
$4.15B
Latest Revenue (Q)
$1.20B
Main Segment (Y)
Device Products
Main Geography (Y)
United States and Puerto Rico
Bausch + Lomb Revenue by Period
Bausch + Lomb Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $4.15B | 10.03% |
2022-12-31 | $3.77B | 0.08% |
2021-12-31 | $3.77B | 10.35% |
2020-12-31 | $3.41B | -9.69% |
2019-12-31 | $3.78B | 3.08% |
2018-12-31 | $3.67B | - |
Bausch + Lomb Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $1.20B | -1.64% |
2024-06-30 | $1.22B | 10.65% |
2024-03-31 | $1.10B | -6.31% |
2023-12-31 | $1.17B | 16.48% |
2023-09-30 | $1.01B | -2.71% |
2023-06-30 | $1.03B | 11.17% |
2023-03-31 | $931.00M | -6.53% |
2022-12-31 | $996.00M | 5.73% |
2022-09-30 | $942.00M | 0.11% |
2022-06-30 | $941.00M | 5.85% |
2022-03-31 | $889.00M | -11.19% |
2021-12-31 | $1.00B | 5.48% |
2021-09-30 | $949.00M | 1.61% |
2021-06-30 | $934.00M | 6.02% |
2021-03-31 | $881.00M | -6.67% |
2020-12-31 | $944.00M | 3.06% |
2020-09-30 | $916.00M | 18.04% |
2020-06-30 | $776.00M | - |
2020-03-31 | $776.00M | - |
Bausch + Lomb Revenue Breakdown
Bausch + Lomb Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 |
---|---|---|
Device Products | $1.65B | - |
Over the Counter Products | $1.61B | - |
Pharmaceutical Products | $618.00M | - |
Branded and Other Generic Products | $252.00M | - |
Other Revenues | $15.00M | - |
Product | - | $3.75B |
Product and Service, Other | - | $22.00M |
Quarterly Revenue by Product
Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|---|---|---|---|---|---|---|---|
Branded and Other Generic Products | $70.00M | $76.00M | $66.00M | $180.00M | $72.00M | - | - | - | - | - | - |
Device Products | $455.00M | $445.00M | $424.00M | $1.24B | $411.00M | - | - | - | - | - | - |
Other Revenues | $4.00M | $3.00M | $5.00M | $12.00M | $3.00M | - | - | - | - | - | - |
Over the Counter Products | $420.00M | $447.00M | $395.00M | $1.20B | $408.00M | - | - | - | - | - | - |
Pharmaceutical Products | $247.00M | $245.00M | $209.00M | $505.00M | $113.00M | - | - | - | - | - | - |
Product | - | - | - | - | - | $1.03B | $928.00M | $991.00M | $937.00M | $935.00M | $883.00M |
Product and Service, Other | - | - | - | - | - | $4.00M | $3.00M | $5.00M | $5.00M | $6.00M | $6.00M |
Bausch + Lomb Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 |
---|---|---|
JAPAN | $187.00M | $192.00M |
KOREA, REPUBLIC OF | $46.00M | $44.00M |
CANADA | $110.00M | $101.00M |
CHINA | $344.00M | $343.00M |
FRANCE | $210.00M | $195.00M |
GERMANY | $147.00M | $138.00M |
MEXICO | $68.00M | $55.00M |
Other Countries | $655.00M | $572.00M |
POLAND | $51.00M | $44.00M |
SPAIN | $85.00M | $77.00M |
United States and Puerto Rico | $1.93B | $1.70B |
ITALY | $82.00M | $72.00M |
Quarterly Revenue by Country
Country | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|---|---|---|---|---|---|---|---|
MEXICO | $18.00M | $20.00M | $17.00M | $18.00M | $19.00M | $15.00M | $16.00M | $16.00M | $14.00M | $14.00M | $11.00M |
KOREA, REPUBLIC OF | $12.00M | $11.00M | $12.00M | $11.00M | $12.00M | $12.00M | $11.00M | $11.00M | $11.00M | $11.00M | $11.00M |
JAPAN | $45.00M | $43.00M | $42.00M | $48.00M | $45.00M | $46.00M | $48.00M | $49.00M | $46.00M | $47.00M | $50.00M |
FRANCE | $52.00M | $64.00M | $60.00M | $45.00M | $47.00M | $62.00M | $56.00M | $41.00M | $43.00M | $56.00M | $55.00M |
CANADA | $33.00M | $32.00M | $28.00M | $30.00M | $27.00M | $27.00M | $26.00M | $28.00M | $27.00M | $24.00M | $22.00M |
CHINA | $92.00M | $93.00M | $77.00M | $94.00M | $87.00M | $89.00M | $74.00M | $92.00M | $93.00M | $76.00M | $82.00M |
ITALY | $22.00M | $23.00M | $23.00M | $21.00M | $19.00M | $22.00M | $20.00M | $15.00M | $16.00M | $21.00M | $20.00M |
GERMANY | $38.00M | $40.00M | $42.00M | $32.00M | $33.00M | $40.00M | $42.00M | $32.00M | $30.00M | $33.00M | $43.00M |
United States and Puerto Rico | $609.00M | $610.00M | $537.00M | $593.00M | $471.00M | $466.00M | $404.00M | $454.00M | $425.00M | $430.00M | $386.00M |
SPAIN | $20.00M | $25.00M | $21.00M | $23.00M | $18.00M | $24.00M | $20.00M | $21.00M | $15.00M | $22.00M | $19.00M |
POLAND | $17.00M | $18.00M | $15.00M | $14.00M | $11.00M | $14.00M | $12.00M | $11.00M | $10.00M | $12.00M | $11.00M |
Other Countries | $174.00M | $175.00M | $166.00M | $214.00M | $150.00M | $152.00M | $139.00M | $157.00M | $142.00M | $138.00M | $126.00M |
AUSTRALIA | - | - | - | - | $11.00M | $11.00M | $10.00M | - | - | - | - |
SWEDEN | - | - | - | - | - | - | - | - | - | - | $9.00M |
Bausch + Lomb Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BDX | Becton, Dickinson and Company | $19.37B | $4.99B |
ALC | Alcon | $10.09B | $2.46B |
RMD | ResMed | $4.69B | $1.22B |
BLCO | Bausch + Lomb | $4.15B | $1.20B |
HOLX | Hologic | $4.03B | $1.01B |
COO | Cooper Companies | $3.59B | $1.00B |
ATR | AptarGroup | $3.49B | $909.29M |
TFX | Teleflex | $2.97B | $764.38M |
WST | West Pharmaceutical Services | $2.95B | $746.90M |
ICUI | ICU Medical | $2.26B | $596.46M |
HAE | Haemonetics | $1.31B | $336.17M |
ATRC | AtriCure | $399.25M | $115.91M |
ANGO | AngioDynamics | $303.91M | $67.49M |
AKYA | Akoya Biosciences | $96.63M | $23.16M |
ATRI | Atrion | - | $48.77M |
BLCO Revenue FAQ
What is Bausch + Lomb’s yearly revenue?
Bausch + Lomb's yearly revenue for 2023 was $4.15B, representing an increase of 10.03% compared to 2022. The company's yearly revenue for 2022 was $3.77B, representing an increase of 0.08% compared to 2021. BLCO's yearly revenue for 2021 was $3.76B, representing an increase of 10.35% compared to 2020.
What is Bausch + Lomb’s quarterly revenue?
Bausch + Lomb's quarterly revenue for Q3 2024 was $1.2B, a -1.64% decrease from the previous quarter (Q2 2024), and a 18.77% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.22B, a 10.65% increase from the previous quarter (Q1 2024), and a 17.49% increase year-over-year (Q2 2023). BLCO's quarterly revenue for Q1 2024 was $1.1B, a -6.31% decrease from the previous quarter (Q4 2023), and a 18.05% increase year-over-year (Q1 2023).
What is Bausch + Lomb’s revenue growth rate?
Bausch + Lomb's revenue growth rate for the last 3 years (2021-2023) was 10.12%, and for the last 5 years (2019-2023) was 9.74%.
What are Bausch + Lomb’s revenue streams?
Bausch + Lomb's revenue streams in c 23 are Device Products, Over the Counter Products, Pharmaceutical Products, Branded and Other Generic Products, and Other Revenues. Device Products generated $1.65B in revenue, accounting 39.80% of the company's total revenue Over the Counter Products generated $1.61B in revenue, accounting 38.86% of the company's total revenue Pharmaceutical Products generated $618M in revenue, accounting 14.91% of the company's total revenue Branded and Other Generic Products generated $252M in revenue, accounting 6.08% of the company's total revenue Other Revenues generated $15M in revenue, accounting 0.36% of the company's total revenue
What is Bausch + Lomb’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Bausch + Lomb was Device Products. This segment made a revenue of $1.65B, representing 39.80% of the company's total revenue.